Genomic alterations and possible druggable mutations in carcinoma of unknown primary (CUP)

Abstract Carcinoma of Unknown Primary (CUP) is a heterogeneous and metastatic disease where the primary site of origin is undetectable. Currently, chemotherapy is the only state-of-art treatment option for CUP patients. The molecular profiling of the tumour, particularly mutation detection, offers a...

Full description

Bibliographic Details
Main Authors: Hamidreza Aboulkheyr Es, Hamid Mahdizadeh, Amir Abbas Hedayati Asl, Mehdi Totonchi
Format: Article
Language:English
Published: Nature Portfolio 2021-07-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-94678-4
_version_ 1818570459023671296
author Hamidreza Aboulkheyr Es
Hamid Mahdizadeh
Amir Abbas Hedayati Asl
Mehdi Totonchi
author_facet Hamidreza Aboulkheyr Es
Hamid Mahdizadeh
Amir Abbas Hedayati Asl
Mehdi Totonchi
author_sort Hamidreza Aboulkheyr Es
collection DOAJ
description Abstract Carcinoma of Unknown Primary (CUP) is a heterogeneous and metastatic disease where the primary site of origin is undetectable. Currently, chemotherapy is the only state-of-art treatment option for CUP patients. The molecular profiling of the tumour, particularly mutation detection, offers a new treatment approach for CUP in a personalized fashion using targeted agents. We analyzed the mutation and copy number alterations profile of 1709 CUP samples deposited in the AACR Project Genomics Evidence Neoplasia Information Exchange (GENIE) cohort and explored potentially druggable mutations. We identified 52 significant mutated genes (SMGs) among CUP samples, in which 13 (25%) of SMGs were potentially targetable with either drugs are approved for the know primary tumour or undergoing clinical trials. The most variants detected were TP53 (43%), KRAS (19.90%), KMT2D (12.60%), and CDKN2A (10.30%). Additionally, using pan-cancer analysis, we found similar variants of TERT promoter in CUP and NSCLC samples, suggesting that these mutations may serve as a diagnostic marker for identifying the primary tumour in CUP. Taken together, the mutation profiling analysis of the CUP tumours may open a new way of identifying druggable targets and consequently administrating appropriate treatment in a personalized manner.
first_indexed 2024-12-14T13:41:35Z
format Article
id doaj.art-f1fe39e7ef8448c2826eda7bf9a46cfb
institution Directory Open Access Journal
issn 2045-2322
language English
last_indexed 2024-12-14T13:41:35Z
publishDate 2021-07-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj.art-f1fe39e7ef8448c2826eda7bf9a46cfb2022-12-21T22:59:26ZengNature PortfolioScientific Reports2045-23222021-07-0111111110.1038/s41598-021-94678-4Genomic alterations and possible druggable mutations in carcinoma of unknown primary (CUP)Hamidreza Aboulkheyr Es0Hamid Mahdizadeh1Amir Abbas Hedayati Asl2Mehdi Totonchi3Department of Genetics, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECRDepartment of Genetics, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECRDepartment of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECRDepartment of Genetics, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECRAbstract Carcinoma of Unknown Primary (CUP) is a heterogeneous and metastatic disease where the primary site of origin is undetectable. Currently, chemotherapy is the only state-of-art treatment option for CUP patients. The molecular profiling of the tumour, particularly mutation detection, offers a new treatment approach for CUP in a personalized fashion using targeted agents. We analyzed the mutation and copy number alterations profile of 1709 CUP samples deposited in the AACR Project Genomics Evidence Neoplasia Information Exchange (GENIE) cohort and explored potentially druggable mutations. We identified 52 significant mutated genes (SMGs) among CUP samples, in which 13 (25%) of SMGs were potentially targetable with either drugs are approved for the know primary tumour or undergoing clinical trials. The most variants detected were TP53 (43%), KRAS (19.90%), KMT2D (12.60%), and CDKN2A (10.30%). Additionally, using pan-cancer analysis, we found similar variants of TERT promoter in CUP and NSCLC samples, suggesting that these mutations may serve as a diagnostic marker for identifying the primary tumour in CUP. Taken together, the mutation profiling analysis of the CUP tumours may open a new way of identifying druggable targets and consequently administrating appropriate treatment in a personalized manner.https://doi.org/10.1038/s41598-021-94678-4
spellingShingle Hamidreza Aboulkheyr Es
Hamid Mahdizadeh
Amir Abbas Hedayati Asl
Mehdi Totonchi
Genomic alterations and possible druggable mutations in carcinoma of unknown primary (CUP)
Scientific Reports
title Genomic alterations and possible druggable mutations in carcinoma of unknown primary (CUP)
title_full Genomic alterations and possible druggable mutations in carcinoma of unknown primary (CUP)
title_fullStr Genomic alterations and possible druggable mutations in carcinoma of unknown primary (CUP)
title_full_unstemmed Genomic alterations and possible druggable mutations in carcinoma of unknown primary (CUP)
title_short Genomic alterations and possible druggable mutations in carcinoma of unknown primary (CUP)
title_sort genomic alterations and possible druggable mutations in carcinoma of unknown primary cup
url https://doi.org/10.1038/s41598-021-94678-4
work_keys_str_mv AT hamidrezaaboulkheyres genomicalterationsandpossibledruggablemutationsincarcinomaofunknownprimarycup
AT hamidmahdizadeh genomicalterationsandpossibledruggablemutationsincarcinomaofunknownprimarycup
AT amirabbashedayatiasl genomicalterationsandpossibledruggablemutationsincarcinomaofunknownprimarycup
AT mehditotonchi genomicalterationsandpossibledruggablemutationsincarcinomaofunknownprimarycup